Home > Boards > US Listed > Biotechs >

Genfit SA (GNFTF)

Add GNFTF Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 12/18/2021 12:40:03 AM - Followers: 3 - Board type: Free - Posts Today: 0

Homepage | Biopharmaceutical company | Genfit

Business Summary
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, primarily in the field of hepato-gastroenterology worldwide. It offers diagnostic solutions in various therapeutic areas, such as metabolic diseases, liver diseases, non-alcoholic steato-hepatitis (NASH), cholestatic liver diseases, inflammation and autoimmune diseases, and inflammatory bowel diseases. The company’s lead pipeline product comprises GFT505, which is in Phase II clinical trials for the treatment of NASH. It is also developing TGFTX1 program that targets the ROR?t receptor, which directs IL-17 mediated immunity to treat inflammatory and auto-immune diseases; and TGFTX3 program that develops proprietary compounds, which activate the nuclear receptor Rev-Erba for metabolic and inflammatory diseases, including NASH and type 2 diabetes. The company also develops TGFTX4 program that inhibits the proliferation and the pro-fibrotic activation of primary human hepatic stellate cells; TGFTX5 program for chronic inflammatory bowel diseases; and SAN/GFT-2 program to develop molecules, which correct the mitochondrial dysfunction associated with certain pathologies comprising type 2 diabetes and kidney diseases. Genfit SA was founded in 1999 and is headquartered in Loos, France

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GNFTF News: Kepler Capital Maintains Their Buy Rating on Genfit (GNFTF) 05/17/2022 05:40:31 PM
GNFTF News: Kepler Capital Maintains a Buy Rating on Genfit (GNFTF) 05/13/2022 05:40:36 PM
GNFTF News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 04/29/2022 12:26:08 PM
GNFTF News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 04/27/2022 05:44:02 AM
GNFTF News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 04/20/2022 12:11:14 PM
News News Alert: Kepler Capital Maintains Their Buy Rating on Genfit (GNFTF) 05/17/2022 05:40:31 PM
#26   GNFT - Friday Rundown, Monday Expectations Jake L 12/18/21 12:40:03 AM
#25   GNFT formally axes NASH drug—will continue work on DewDiligence 07/22/20 04:52:53 PM
#24   Genfit claims advance in non-invasive NASH diagnostic: #msg-132439027. DewDiligence 06/23/17 11:23:36 AM
#23   Phase-3 NASH trial has slower-than-expected enrollment: #msg-130748127. DewDiligence 04/24/17 11:32:42 AM
#22   Big event happening March 9th!!! Orangefan1974 03/02/17 07:25:00 PM
#21   yea good pop tho gregque 03/02/17 10:43:38 AM
#20   At this point, it's merely a rumor—not real news. DewDiligence 03/02/17 10:37:42 AM
#19   thnx DD great news wow gregque 03/02/17 10:31:23 AM
#18   GNFT.PA +29% on SA piece re NVS buyout rumor: DewDiligence 03/02/17 10:29:00 AM
#17   ive heard nothing yet gregque 03/02/17 07:19:52 AM
#16   Any news? RTR-1 03/01/17 09:54:41 PM
#15   HAPPY NEW YEAR gregque 01/04/17 07:22:38 PM
#14   buying all i can gregque 01/04/17 04:19:28 PM
#13   im long GNFTF the uplisting to nasdaq is gregque 12/30/16 11:55:49 AM
#12   GENFIT ANNOUNCES POSITIVE RESULTS FROM Wildbilly 09/15/15 10:40:08 PM
#11   Dump Intercept And Buy Genfit Wildbilly 06/19/15 12:48:11 PM
#10   Genfit: Why Intercept's NASH Phase 3 Design Is Wildbilly 05/20/15 09:46:13 AM
#9   LOL $73.10 x 48.29 they really need to Wildbilly 04/21/15 03:54:02 PM
#8   $GNFTF recent news/filings stocktrademan 04/16/15 11:55:35 AM
#7   Genfit: Refuting Bearish Arguments About Genfit's Results - Wildbilly 04/06/15 08:58:01 PM
#6   Genfit: Misunderstandings And Propaganda About Phase 2b Results Wildbilly 03/31/15 07:35:37 PM
#5   Conference call 2:30 EDT Thurs. 3/26/2015 Wildbilly 03/26/15 02:19:21 PM
#4   Genfit to conduct large liver drug trial despite Wildbilly 03/26/15 02:12:02 PM
#3   Genfit phase-2 NASH trial misses primary endpoint, Wildbilly 03/26/15 01:30:40 PM
#2   Genfit Next Up In The M&A Rumor Mill Wildbilly 03/24/15 10:56:49 PM
#1   FDA grants Fast Track designation to GFT505 in NASH Wildbilly 03/24/15 10:24:45 PM
Consent Preferences